Biomarker Identification & Selection

• One-Stop CAR-T Therapy Development Services
• TCR Modified T Cell Development Services
• End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services
• TCR-Like Antibody Services
• Dendritic Cell Vaccine Development Services
• Bispecific TCR Development Service
• Drug Discovery Assay for Cytokine Storm Inhibition

Biomarker Identification & Selection

In a broad sense, cancer biomarker is an indicative of the presence of cancer in the body or a molecule secreted by a tumor or a specific response of the body to the presence of cancer. It is usually identifiable or measurable in the blood, urine or other convenient body fluids by PCR, ELISA, and other conventional immune assays. In this sense, biomarkers can be categorized into genetic, epigenetic, proteomic, glycomic, and imaging biomarkers for cancer diagnosis, prognosis, and epidemiology. In a narrow sense of cancer biomarker, it is limited to proteins the most used to challenge in the clinical applications, especially in the CAR-T therapy. Specifically, a cancer biomarker of the CAR-T provides the most prominent signal of cancer cells for distinguishing from normal cells and the most effective target for immune recognition and destruction. As the most basic foundation of therapeutic effect, these cancer biomarkers commonly possess the following characteristics:

1. Involve in the canceration process, correlate with the disease changes, like deterioration and improvement;
2. Manifest as a relatively high expression or even unique expression on the surface of cancerous and precancerous tissue than other normal cells to be measured and distinguished easily and reliably for an acceptable safety, especially the mutant proteins, which is the most specific biomarkers for the only origination from an existing tumor;
3. Relatively stable in response to other unrelated factors.

At Creative Biolabs, we provide almost all the discovered cancer targets and novel ones in the evaluation for CAR-T therapy. Like AFP for liver cancer, BCR-ABL for chronic myeloid leukemia, BRCA1/BRCA2 for breast/ovarian cancer, BRAF V600E for melanoma/colorectal cancer, CA-125 for ovarian cancer, CA19.9 for pancreatic cancer, CEA for colorectal cancer, EGFR for non-small-cell lung carcinoma, HER-2 for breast cancer, KIT for gastrointestinal stromal tumor, PSA for prostate cancer, S100 for melanoma, etc.  

Creative Biolabs offers the world leading custom CellRapeutics™ Chimeric Antigen Receptor (CAR) service with the most advanced techniques and years of experiences to establish the solid platform for CAR production.

1. Recommend the most applicable target according to specific type of cancer and customs requirements, or design subsequent and further technique service based on designated target;
2. Screen originally for novel potential target based on customized conditions, which is an advanced optional service with relatively higher technique requirement and price.

Since we can develop CAR-T therapy aiming at any target in our growing database with more than 1,000 cancer biomarkers, the most professional and sophisticated services are at Creative Biolabs. 

CAR Biomarker indentification & selection High affinity scFv generation CAR design & construction Virus packaging & CAR transfection CAR in vitro assay CAR Pre-clinical in vivo assay CAR clinical trial